Stanislas Pol

Summary

Country: France

Publications

  1. ncbi request reprint [Should HCV patients co-infected with HIV be treated? When? How?]
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    Med Mal Infect 34:22-4. 2004
  2. ncbi request reprint Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers
    Maryline Mancini-Bourgine
    Carcinogénèse Hépatique et Virologie Moléculaire Institut National de la Santé et de la Recherche Médicale Unité 370, Institut Pasteur, Paris, France
    Hepatology 40:874-82. 2004
  3. ncbi request reprint Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
    Michal Abel
    INSERM, U561 Equipe AVENIR, Paris, France
    Hepatology 44:1607-16. 2006
  4. ncbi request reprint Therapeutic vaccination in chronic hepatitis B virus carriers
    Stanislas Pol
    Unité d Hépatologie, Liver Unit, Hopital Cochin, Université Paris V René Descartes and Inserm U 567, 27 Rue du Faubourg Saitn Antoine, 75014 Paris, France
    Expert Rev Vaccines 5:707-16. 2006
  5. doi request reprint Management of chronic hepatitis C virus infection in HIV-infected patients
    Stanislas Pol
    Liver Unit, Universite Paris Descartes, Hopital Cochin, Paris, France
    Clin Infect Dis 47:94-101. 2008
  6. ncbi request reprint Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker Enfants Malades, Paris, France
    Hepatology 31:1338-44. 2000
  7. ncbi request reprint [Management of C virus infection in patients coinfected with HIV treated with antiretroviral agents]
    S Pol
    Service d Hepatologie, Hopital Necker, 149, rue de Sevres, F 75743 Paris
    Presse Med 30:677-82. 2001
  8. ncbi request reprint Efficacy and limitations of a specific immunotherapy in chronic hepatitis B
    S Pol
    Unité d Hépatologie, Hĵpital Necker, Paris, France
    J Hepatol 34:917-21. 2001
  9. ncbi request reprint Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris, France
    J Viral Hepat 9:1-8. 2002
  10. ncbi request reprint HCV infection and hemodialysis
    Stanislas Pol
    Unité d Hépatologie et Inserm V 370, Hopital Necker, Paris, France
    Semin Nephrol 22:331-9. 2002

Detail Information

Publications109 found, 100 shown here

  1. ncbi request reprint [Should HCV patients co-infected with HIV be treated? When? How?]
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    Med Mal Infect 34:22-4. 2004
  2. ncbi request reprint Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers
    Maryline Mancini-Bourgine
    Carcinogénèse Hépatique et Virologie Moléculaire Institut National de la Santé et de la Recherche Médicale Unité 370, Institut Pasteur, Paris, France
    Hepatology 40:874-82. 2004
    ..We demonstrate that DNA vaccination can specifically but transiently activate T-cell responses in some chronic HBV carriers who do not respond to current antiviral therapies...
  3. ncbi request reprint Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
    Michal Abel
    INSERM, U561 Equipe AVENIR, Paris, France
    Hepatology 44:1607-16. 2006
    ..Therapeutic modulation of the intrahepatic balance between specific and bystander CD8 T cells might be beneficial in patients with chronic hepatitis C...
  4. ncbi request reprint Therapeutic vaccination in chronic hepatitis B virus carriers
    Stanislas Pol
    Unité d Hépatologie, Liver Unit, Hopital Cochin, Université Paris V René Descartes and Inserm U 567, 27 Rue du Faubourg Saitn Antoine, 75014 Paris, France
    Expert Rev Vaccines 5:707-16. 2006
    ....
  5. doi request reprint Management of chronic hepatitis C virus infection in HIV-infected patients
    Stanislas Pol
    Liver Unit, Universite Paris Descartes, Hopital Cochin, Paris, France
    Clin Infect Dis 47:94-101. 2008
    ..Effective management strategies that encompass patient and viral factors are necessary to improve the long-term outlook for coinfected patients...
  6. ncbi request reprint Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker Enfants Malades, Paris, France
    Hepatology 31:1338-44. 2000
    ..In 1b-infected patients, the combination of high doses of interferon-alfa (6 MU) and ribavirin for 12 months appears to be the best therapy, with a high rate of sustained response...
  7. ncbi request reprint [Management of C virus infection in patients coinfected with HIV treated with antiretroviral agents]
    S Pol
    Service d Hepatologie, Hopital Necker, 149, rue de Sevres, F 75743 Paris
    Presse Med 30:677-82. 2001
    ..The two viral infections can be treated simultaneously or, on the contrary, one may be given priority depending on the respective pathological or viral situations...
  8. ncbi request reprint Efficacy and limitations of a specific immunotherapy in chronic hepatitis B
    S Pol
    Unité d Hépatologie, Hĵpital Necker, Paris, France
    J Hepatol 34:917-21. 2001
    ..This controlled study aimed to evaluate the efficacy and potential side effects of hepatitis B virus (HBV) vaccination as active immunotherapy in HBV-related chronic hepatitis...
  9. ncbi request reprint Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy
    S Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris, France
    J Viral Hepat 9:1-8. 2002
    ....
  10. ncbi request reprint HCV infection and hemodialysis
    Stanislas Pol
    Unité d Hépatologie et Inserm V 370, Hopital Necker, Paris, France
    Semin Nephrol 22:331-9. 2002
    ..Indeed, alpha-interferon is contraindicated in kidney recipients given the risk for rejection. Preventive treatment for HCV is only respect for universal hygiene rules in the dialysis setting because there is no available vaccine...
  11. ncbi request reprint HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms
    Stanislas Pol
    Unité d Hépatologie and INSERM U 370, Hopital Necker, Paris, France
    Clin Infect Dis 38:S65-72. 2004
    ..g., methamphetamine). A better understanding of these complex interactions, including adjustments of dosages of antiretroviral drugs, will probably help in the management of HIV-infected patients with liver enzyme abnormalities...
  12. ncbi request reprint [Treatment of delta (type D) hepatitis]
    Stanislas Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris, France
    Gastroenterol Clin Biol 29:384-7. 2005
  13. ncbi request reprint [Epidemiology and natural history of hepatitis B]
    Stanislas Pol
    Hopital Necker, 75743 Paris Cedex 15
    Rev Prat 55:599-606. 2005
    ..HBV chronic infection is a problem of public health, particularly in developing countries, evidencing the need for universal HBV vaccination...
  14. ncbi request reprint Improving anti-hepatitis C virus therapy
    Stanislas Pol
    Hopital Necker, APHP, Unité d Hépatologie, 149 rue de Sevres, 75015 Paris Cedex 15, France
    Expert Opin Biol Ther 6:923-33. 2006
    ....
  15. ncbi request reprint [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]
    Marc Bourliere
    Service d Hepato Gastroenterologie, Hopital Saint Joseph, 26 bd de Louvain, 13008 Marseille, France
    Gastroenterol Clin Biol 30:3S34-6. 2006
  16. ncbi request reprint Optimizing treatment outcomes in chronic hepatitis C: management of non-response
    Stanislas Pol
    Unité d Hépatologie, Inserm U 567 Hôpital Cochin, Paris, France
    Antivir Ther 11:955-70. 2006
    ..This review explores putative management strategies for patients who have previously failed to achieve a response to IFN-based therapy, and summarises retreatment options that have been, and are currently being evaluated...
  17. ncbi request reprint Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy
    Jeanne Serpaggi
    Hepatology Unit, Necker Hospital, Paris, France
    AIDS 20:233-40. 2006
    ....
  18. doi request reprint Management of hepatitis C virus infection in heavy drinkers
    Charlotte E Costentin
    Unité d Hépatologie et d Addictologie, Hopital Cochin, Assistance Publique des Hopitaux de Paris, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Alcohol Alcohol 48:337-42. 2013
    ..Optimal management of hepatitis C virus (HCV) infection is controversial in heavy drinkers. We compared the management of HCV infection of heavy drinkers with that of patients without a history of alcohol abuse...
  19. ncbi request reprint Reversibility of cirrhosis in HIV/HBV coinfection
    Vincent O Mallet
    Universite Paris Descartes, Paris, France
    Antivir Ther 12:279-83. 2007
    ..In conclusion, a HAART regimen including tenofovir disoproxil fumarate in a HBV/HIV-coinfected cirrhotic patient might lead to sustained HBV viral suppression and result in cirrhosis reversal...
  20. ncbi request reprint Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
    ..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly...
  21. doi request reprint Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers
    Jean Baptiste Trabut
    Unité d Hépatologie et d Addictologie, Hopital Cochin, Assitance Publique Hôpitaux de Paris, France
    Alcohol Clin Exp Res 36:1407-11. 2012
    ..To challenge this hypothesis, we have prospectively tested the short-term impact of alcohol withdrawal on LS value...
  22. ncbi request reprint FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest
    Anais Vallet-Pichard
    Universite Paris Descartes, Paris, France
    Hepatology 46:32-6. 2007
    ..45 or >3.25 (kappa = 0.561, P < 0.01). A FIB-4 value <1.45 or >3.25 (64.6% of the cases) was concordant with FibroTest results in 92.1% and 76%, respectively...
  23. ncbi request reprint Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:35-42. 2008
    ..To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006...
  24. ncbi request reprint The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus
    Pascal Lebray
    Unité d Hépatologie, Hopital Necker, Paris, France
    Antivir Ther 10:769-76. 2005
    ..To evaluate the benefits of haematopoietic growth factors (HGFs) during the treatment of chronic hepatitis C virus (HCV) infection with severe haematotoxicity...
  25. doi request reprint Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease
    Patrick Soussan
    Pathogenèse des Hépatites Virales B et Immunothérapie, Institut National de la Santé et de la Recherche Médicale U845, Paris, France
    J Infect Dis 198:218-25. 2008
    ..The present study was designed to quantify the expression of defective HBV (dHBV) and wild-type HBV (wtHBV) genomes in the serum of patients with HBV infection and its relation to the severity of liver disease...
  26. doi request reprint Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    Antivir Ther 14:839-45. 2009
    ..The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients...
  27. doi request reprint Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
    Olivier Mir
    Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors CERIA, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, 27, rue du Faubourg Saint Jacques, 75014, Paris, France
    Med Oncol 29:2793-9. 2012
    ..8) vs. 3.8 months (95% CI: 2.5-3.9), p=0.017]. In our experience, gemcitabine-oxaliplatin was feasible and had detectable clinical activity in HCC patients pre-treated with sorafenib. Further studies are needed to confirm these findings...
  28. ncbi request reprint Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM V707, Paris, France
    AIDS 20:525-31. 2006
    ..To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients...
  29. doi request reprint Hepatitis C: epidemiology, diagnosis, natural history and therapy
    Stanislas Pol
    Universite Paris Descartes, APHP, Hopital Cochin, Unité d Hépatologie, Institut Cochin, Paris, France
    Contrib Nephrol 176:1-9. 2012
    ..The next step appears to be the combination of these oral drugs allowing a better safety and efficacy of the treatment...
  30. ncbi request reprint Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C
    Sylvia Males
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    Antivir Ther 12:797-803. 2007
    ..To analyse the association between serum alpha-foetoprotein (AFP) levels and sustained virological response (SVR) in treated patients...
  31. ncbi request reprint [Management of HCV-HIV patients]
    Stanislas Pol
    Unité d Hépatologie, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Gastroenterol Clin Biol 31:4S7-12. 2007
    ..The harmful impact of HIV underlines the need for improving:..
  32. doi request reprint New trends in hepatitis C management
    Vincent Mallet
    Paris Descartes University, Department of Hepatology, APHP, Cochin Hospital, INSERM U 567, F 75014, Paris, France
    Presse Med 39:446-51. 2010
    ..Current epidemiologic models suggest that the incidence of HCC and of the mortality associated with chronic HCV infection will continue to increase through 2015, a finding consisting with the perception of liver specialists today...
  33. pmc Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
    Olivier Mir
    Centre for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    PLoS ONE 7:e37563. 2012
    ..Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated with poor performance status and shortened survival in cancer patients...
  34. ncbi request reprint Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C
    Helene Fontaine
    Unité d Hépatologie, Hopital Necker, Paris, France
    Transplantation 78:853-7. 2004
    ..The aim of this study was to analyze the biologic, virologic, and histopathologic efficacy of ribavirin alone in kidney allograft recipients with hepatitis C...
  35. doi request reprint Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection
    Simona Cosconea
    Universite Paris Descartes, Unité d Hépatologie, Assistance Publique Hopitaux de Paris, Hôpital Cochin et Inserm U 1016, France
    J Hepatol 57:55-60. 2012
    ..We evaluated the benefit associated with HBV viral suppression by nucleos(t)ide analogues treatment in HBV-infected kidney recipients...
  36. ncbi request reprint Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus
    Anne Varaut
    Liver Diseases Unit, INSERM U 370, Pathological Anatomy Department, Hopital Necker, 149 rue de Sevres, 75015 Paris, France
    Transplantation 80:1550-5. 2005
    ..The aim of this study was to assess the diagnostic accuracy of the fibrotest (a noninvasive method to assess liver fibrosis in HCV on a scale from 0 to 1) in hemodialysis and renal transplant patients infected by chronic HCV...
  37. ncbi request reprint [Natural history of hepatitis B infection]
    Stanislas Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris
    Presse Med 35:308-16. 2006
    ..Chronic HBV infection is a major public health problem, particularly in developing countries, and it requires that efforts to make HBV vaccination universal be intensified...
  38. pmc Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination
    Daniel Scott-Algara
    Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France
    PLoS ONE 5:e8761. 2010
    ..We previously reported the induction or reactivation of T cell responses in chronic hepatitis B patients vaccinated with a DNA encoding hepatitis B envelope proteins during a phase I clinical trial...
  39. doi request reprint Treatment of hepatitis C virus genotype 3-infection
    Stanislas Pol
    Universite Paris Descartes, APHP, Unité d Hépatologie, Hopital Cochin, Inserm U 1016, Institut Cochin, Paris, France
    Liver Int 34:18-23. 2014
    ..The oral combination of new DAAs (dual or triple combination of different antivirals) or of DAAs and host targets such as cyclophilin will probably become the SOC for genotype 3-infected treatment-naïve or -experienced patients. ..
  40. ncbi request reprint Reversibility of hepatitis C virus-related cirrhosis
    Stanislas Pol
    Unité d Hépatologie, Hopital Necker, Paris, France
    Hum Pathol 35:107-12. 2004
    ..In conclusion, long-lasting suppression of the necroinflammatory activity of liver disease and/or antifibrogenetic effects of interferon-alpha may allow regression of cirrhosis...
  41. ncbi request reprint Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency
    Helene Fontaine
    Liver Unit, Necker Hospital, Paris, France
    Transplantation 80:1086-92. 2005
    ..This study analyzes the biochemical, serological, and virological efficacy and the safety of adefovir dipivoxil in patients with renal disturbances...
  42. ncbi request reprint Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers
    Maryline Mancini-Bourgine
    Carcinogénèse Hépatique et Virologie Moléculaire, Institut National de la Santé et de la Recherche Médicale Unité 370, Département de Médecine Moléculaire, Institut Pasteur, 25 28 Rue du Dr Roux, 75015 Paris, France
    Vaccine 24:4482-9. 2006
    ..This study shows evidences for the safety and immunological efficacy of HBV-DNA vaccination and demonstrates that DNA vaccination can restore or activate T-cell responses in chronic HBV carriers...
  43. ncbi request reprint High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, Paris, France
    AIDS 21:1645-8. 2007
    ..Antiretroviral therapy in general was independently associated with lower HCV viral load. This suggests that HCV viral load kinetics could differ according to the choice of HAART regimen...
  44. ncbi request reprint Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy
    Jean David Zeitoun
    AP HP, Hopital Cochin, Hepatologie, Paris, France
    J Clin Virol 40:71-3. 2007
    ..The respective effect of immune restoration and of high doses of ritonavir are discussed...
  45. ncbi request reprint Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV in the HAART era: the role of mixed steatosis
    Fanny Lanternier
    Service des Maladies Infectieuses et Tropicales, Hopital Cochin, 149 rue de Sevres, Paris
    Gastroenterol Clin Biol 31:822-7. 2007
    ..In this cohort of HIV/HCV coinfected intravenous drug user patients, METAVIR activity score, mixed steatosis and a low CD4 cell count were independent factors associated with severe liver fibrosis...
  46. doi request reprint Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men
    Jade Ghosn
    AP HP, EA MRT 3620, Universite Paris Descartes, Department of Virology, Necker Hospital, Paris, France
    AIDS 22:658-61. 2008
    ..HCV serology and serum HCV RNA should be examined periodically in HIV-infected men who have sex with men engaging in high-risk sexual behaviours...
  47. doi request reprint The role of adherence in virological suppression in patients receiving anti-HBV analogues
    Philippe Sogni
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Inserm U 1016, Paris, France
    Antivir Ther 17:395-400. 2012
    ..The aim of this study was to evaluate adherence to anti-HBV analogues and associated virological suppression...
  48. ncbi request reprint Direct and indirect evidence for the reversibility of cirrhosis
    Jeanne Serpaggi
    Service d Hépatologie et INSERM U 567, Hopital Necker Enfants Malades, Paris, France
    Hum Pathol 37:1519-26. 2006
    ..Using repeated liver biopsies, clinicobiochemical, radiologic, and endoscopic tests, we provide evidence for potential reversibility of cirrhosis after long-lasting suppression of the necro-inflammatory activity of liver disease...
  49. ncbi request reprint [Impact of resistance to analogue antivirals and therapeutic strategies in situations of dialysis, kidney transplantation, vasculitis, and preemptive treatments in immunosuppressed patients]
    Stanislas Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, 149, rue de Sevres, 75015 Paris, France
    Gastroenterol Clin Biol 30:3S31-3. 2006
  50. doi request reprint Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:765-73. 2008
    ..To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infected patients...
  51. doi request reprint Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis
    Benjamin Terrier
    Department of Internal Medicine, Universite Pierre et Marie Curie, Paris, France
    J Hepatol 55:756-61. 2011
    ..Data are lacking in HIV-HCV coinfected patients...
  52. ncbi request reprint Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
    Fabrice Carrat
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, Paris, France
    JAMA 292:2839-48. 2004
    ..Most data on the virologic efficacy and safety of the combination of peginterferon alfa-2b and ribavirin in coinfected patients come from uncontrolled studies...
  53. ncbi request reprint Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C
    Vincent Mallet
    Université Paris Descartes Assistance Publique Hôpitaux de Paris, Hopital Cochin, INSERM U 567, Paris, France
    Ann Intern Med 149:399-403. 2008
    ..The effect of regression of cirrhosis in chronic hepatitis C is unknown...
  54. ncbi request reprint [Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance]
    Stanislas Pol
    Unité d hépatologie et Inserm U 370, Hopital Necker, Paris
    Gastroenterol Clin Biol 26:B264-73. 2002
  55. doi request reprint Treatment of HBV-related cirrhosis
    Anais Vallet-Pichard
    Universite Paris Descartes, APHP, INSERM U 567, Hopital Cochin, Unité d Hépatologie, 27 rue du Faubourg Saint Jacques, Paris Cedex 14, France
    Expert Rev Anti Infect Ther 7:527-35. 2009
    ..Patients with cirrhosis require careful monitoring to detect resistance and prevent flares, and also to screen for hepatocellular carcinoma, portal hypertension and liver failure...
  56. ncbi request reprint High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients
    Patrick Marcellin
    Hopital Beaujon, Service d Hepatologie, Clichy, France
    Eur J Gastroenterol Hepatol 22:1290-6. 2010
    ..This study describes the types of therapy used in chronic hepatitis B (CHB) in France and patient characteristics according to therapy...
  57. doi request reprint The impact of human immunodeficiency virus on viral hepatitis
    Vincent Mallet
    Hopital Cochin Saint Vincent de Paul, Unité d Hépatologie, Inserm U 1016, Universite Paris Descartes, Paris, France
    Liver Int 31:135-9. 2011
    ....
  58. ncbi request reprint Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope
    Silvina Laura Malmassari
    INSERM U812, Pathogenèse des Hépatites Virales B et Immunothérapie, Paris, France
    Hepatology 45:1199-209. 2007
    ..We further demonstrated that these viral mutant sequences activated T cells specific for the immunodominant epitope only weakly, if at all. This is the first study linking BCP mutations and HBx-specific T cell responses...
  59. pmc Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection
    Etienne Patin
    Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Necker Medical School, INSERM Unité 980, Paris, France
    Gastroenterology 143:1244-52.e1-12. 2012
    ..Only a fraction of patients with chronic HCV infection develop liver fibrosis, a process that might also be affected by genetic factors. We performed a 2-stage GWA study of liver fibrosis progression related to HCV infection...
  60. doi request reprint Nonalcoholic fatty liver disease and HIV infection
    Anais Vallet-Pichard
    Unité d Hépatologie, Hopital Cochin Saint Vincent de Paul, Universite Paris Descartes, APHP, Paris, France
    Semin Liver Dis 32:158-66. 2012
    ..First-line treatment of NAFLD is mainly based on the adequate management of the metabolic syndrome, including lifestyle changes. Specific therapeutic approaches are under investigation...
  61. doi request reprint Viral hepatitis in solid organ transplantation other than liver
    Anais Vallet-Pichard
    Universite Paris Descartes, Paris, France
    J Hepatol 55:474-82. 2011
    ..Organ transplantations other than kidney (cardiac or pulmonary transplantations) involve the same diagnosis and therapeutic issues...
  62. doi request reprint Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
    Pierre Nahon
    AP HP, Hopital Jean Verdier, Service d Hepatologie, Bondy, France Université Paris 13, Sorbonne Paris Cité, Equipe Labellisée Ligue contre le Cancer, Saint Denis, France INSERM, UMR 1162, Génomique Fonctionnelle des Tumeur Solides, Paris, France Electronic address
    Gastroenterology 152:142-156.e2. 2017
    ..We performed a prospective study to investigate the effects of a sustained viral response (SVR) on outcomes of patients with hepatitis C virus (HCV) infection and compensated cirrhosis...
  63. doi request reprint Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy
    Philippe Sultanik
    Department of Hepatology, Hopital Cochin, AP HP, Paris, France
    Liver Int 35:1833-44. 2015
    ..e., telaprevir/boceprevir) therapy in treatment-experienced cirrhotic patients from the ANRS CUPIC cohort...
  64. pmc Impact of Obliterative Portal Venopathy Associated With Human Immunodeficiency Virus
    Clémence Hollande
    From the Institut Pasteur, Inserm unit U818, Paris, France Paris Descartes University, Paris, France CH, AP HP, Cochin Port Royal Hospital, Liver Unit, Paris, France Cochin Institute, Paris Descartes University, Sorbonne Paris Cité, Paris, France VM, Paris Saclay University, Paris Sud University, CESP, Inserm URM 1178, Villejuif, France University Pierre et Marie Curie, Paris, France AP HP, Beaujon Hospital, Department of Psychiatry and Addictive Medicine, Clichy, France SD AP HP, Cochin Port Royal Hospital, Liver Unit, Paris, France AVP, HF, PS AP HP, Necker Enfants Malades Hospital, Pathology Unit, Paris, France VV AP HP, Cochin Port Royal Hospital, 5323 Harry Hines Boulevard
    Medicine (Baltimore) 95:e3081. 2016
    ..HIVOP is a severe disease associated with high morbidity related to symptomatic portal hypertension, which occurred in 50% and required liver transplantation in 14%...
  65. doi request reprint Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure
    Stanislas Pol
    Universite Paris Descartes, INSERM Unité 1016, and Assistance Publique Hopitaux de Paris, Cochin Hospital, Paris, France
    J Hepatol 58:883-9. 2013
    ..This subanalysis of the REALIZE study evaluated the impact of IL28B polymorphisms on sustained virologic response (SVR) in telaprevir-treated, HCV genotype 1-infected patients with prior PegIFN/RBV treatment failure...
  66. doi request reprint [Hepatitis C virus: 25 years-old, the end?]
    Stanislas Pol
    Universite Paris Descartes, Inserm U1016, Unité d Hépatologie, Hôpital Cochin APHP, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Med Sci (Paris) 29:998-1003. 2013
    ....
  67. ncbi request reprint Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes
    Giovanna Vona
    INSERM U370 Pasteur, Necker Faculty, Paris, France
    J Hepatol 40:682-8. 2004
    ..We have therefore investigated the feasibility of quantifying HCV replication using a laser-based microdissection technique...
  68. pmc Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
    Armanda Casrouge
    The Laboratory of Dendritic Cell Biology, Department of Immunology, Institut Pasteur, Paris, France
    J Clin Invest 121:308-17. 2011
    ..These data offer what we believe to be the first evidence for CXCL10 antagonism in human disease and identify a possible factor contributing to the inability of patients to clear HCV...
  69. ncbi request reprint Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment
    Anais Vallet-Pichard
    Unité d hépatologie et Inserm U 370, Hopital Necker, 149 Rue de S èvres, 75015 Paris, France
    J Hepatol 41:156-66. 2004
  70. ncbi request reprint Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection
    Anais Vallet-Pichard
    Inserm U 370 et Unité d Hépatologie, Hôpital Necker Faculté Paris V, 149 rue de Sevres, 75015 Paris, France
    J Hepatol 44:S28-34. 2006
    ..Several non-exclusive pathogenic processes explain the increasing rate of liver complications associated with HCV-related liver disease...
  71. ncbi request reprint Improving anti-HCV therapy
    Stanislas Pol
    Université Paris Descartes APHP, Hopital Cochin, Hépatologie INSERM U 567, Institut Cochin Paris, France
    Discov Med 6:187-90. 2006
    ..The combination of interferon and ribavirin is effective in many patients. However, the right treatment doses and duration, among other attributes, have a large impact on the treatment outcome...
  72. doi request reprint Influence of liver biopsy on abstinence in alcohol-dependent patients
    Jean Baptiste Trabut
    Unité d Hépatologie Hôpital Cochin, 27, rue du Faubourg St Jacques, 75014 Paris, France
    Alcohol Alcohol 43:559-63. 2008
    ..Liver biopsy indication for the evaluation of alcoholic liver disease is controversial. Our aim was to investigate the influence of the biopsy on the patients' motivation for abstinence...
  73. doi request reprint Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin
    David Ancel
    Hepatology Department, Tenon Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Eur J Gastroenterol Hepatol 21:726-9. 2009
    ..Ribavirin is usually contraindicated in patients with haemolytic anaemia. This pilot study evaluated the efficacy and safety of antiviral treatment in patients with sickle cell disease (SCD) or beta-thalassaemia major (TM)...
  74. doi request reprint Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients
    Vincent O Mallet
    Institut Cochin, Universite Paris Descartes, CNRS, UMR 8104, INSERM, U567, Paris, France
    AIDS 23:1511-8. 2009
    ..To identify the mechanism of nodular regenerative hyperplasia in HIV-infected patients...
  75. doi request reprint Brief communication: case reports of ribavirin treatment for chronic hepatitis E
    Vincent Mallet
    Institut Cochin, Université Paris Descartes Unité Mixte de Recherche S1016, Paris, France
    Ann Intern Med 153:85-9. 2010
    ..There is currently no accepted treatment of chronic hepatitis E virus (HEV) infection...
  76. pmc Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib
    Romain Coriat
    Center for Research on Angiogenesis Inhibitors CERIA, Hopital Cochin, AP HP, Paris, France
    PLoS ONE 6:e16978. 2011
    ..No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients...
  77. ncbi request reprint Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin
    Aurélie Briat
    Virology Laboratory, Universite Rene Descartes, Paris, France
    AIDS 19:1827-35. 2005
    ..To compare the prevalence of hepatitis C (HCV) RNA in semen from men infected with HCV and those coinfected with HIV-1/HCV and to study the origin of HCV shed in semen...
  78. ncbi request reprint [A puzzling case of portal hypertension in a patient with human immunodeficiency and hepatitis C virus co-infection]
    Vincent Mallet
    INSERM U567, Unité d Hépatologie, Pôle d hépato gastroentérologie médicochirurgical, Hopital Cochin, 27 rue du Faubourg Saint Jacques, Paris
    Gastroenterol Clin Biol 31:878-80. 2007
    ..Vascular liver diseases seem to be a new cause of chronic liver disease in HIV-infected patients receiving combined antiretroviral therapy. The syndrome of HIV-associated liver vasculopathy is discussed...
  79. ncbi request reprint [Treatment of hepatitis B. Current strategies]
    Stanislas Pol
    Service d Hepatologie, Hopital Cochin, Paris
    Gastroenterol Clin Biol 31:325-32. 2007
  80. ncbi request reprint [Atheroma and hepatitis C virus]
    Anais Vallet-Pichard
    Unité d Hépatologie et U 370, Hopital Necker, Paris
    Gastroenterol Clin Biol 26:989-90. 2002
  81. ncbi request reprint The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis
    Patrick Soussan
    INSERM U370, CHU Necker and Institut Pasteur, 156 rue de Vaugirard, 75015 Paris, France
    J Hepatol 38:343-8. 2003
    ..The present study was designed to evaluate the impact of HBSP expression on the clinical status and liver pathology of HBV infection...
  82. ncbi request reprint [Liver and ageing: clinical aspects]
    Arnaud Plat
    Unité d Hépatologie Adulte, Hopital Necker Enfants Malades, Paris
    Gastroenterol Clin Biol 27:540-7. 2003
  83. ncbi request reprint Hepatitis B virus genotypes and extrahepatic manifestations
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Hepatol 43:764-70. 2005
    ..This study aimed at correlating the presence of extrahepatic manifestations with hepatitis B virus (HBV) genotypes in patients with chronic HBV infection...
  84. ncbi request reprint Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
    ..To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy...
  85. doi request reprint Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, France
    Clin Infect Dis 46:768-74. 2008
    ..We determined the prevalence and determinants of worsening fibrosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving anti-HCV therapy...
  86. ncbi request reprint Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs
    Caroline Besson
    Service d hématologie adulte, Hopital Necker Enfants Malades, APHP, Paris, France
    J Clin Oncol 24:953-60. 2006
    ..Epidemiologic studies show an association between hepatitis C virus (HCV) and B-cell non-Hodgkin's lymphoma (NHL). Treatment and outcome of patients with diffuse large-cell lymphoma (DLCL) and HCV infection are still a matter of debate...
  87. doi request reprint Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection
    Bertrand Nalpas
    Unité d Hépatologie, Institut National de la Sante et de la Recherche Medicale, U567, Hopital Cochin, Paris, France
    Gut 59:1120-6. 2010
    ..Only a minority of patients with chronic hepatitis C virus (HCV) infection develops severe liver fibrosis, a process that may be controlled by human genetic factors...
  88. ncbi request reprint Severe evolution of chronic hepatitis C in renal transplantation: a case control study
    Hervé Zylberberg
    Service d Hépatologie et INSERM U 370, Hopital Saint Louis, Paris, France
    Nephrol Dial Transplant 17:129-33. 2002
    ..To evaluate the impact of kidney transplantation on histopathological progression of hepatitis C virus (HCV)-related liver disease...
  89. ncbi request reprint Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease
    Sophie Hue
    Laboratory of Immunology, Hopital Necker, Paris, France
    J Infect Dis 186:106-9. 2002
    ..HLA class II alleles may weakly contribute to the severity of HCV liver disease. Of persons infected with HCV, only 15%-20% spontaneously clear the virus, and the rest become chronically infected...
  90. ncbi request reprint Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virus
    Laurent Aaron
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire Necker Enfants Malades, Paris, France
    Clin Infect Dis 40:306-8. 2005
    ..3%) of 19 patients with a CD4 cell count of <200 cells/ micro L (P=.0064). Cell-mediated immunity could, therefore, contribute to the production of HCV-associated cryoglobulins...
  91. pmc Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype
    Hendy Abdoul
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    PLoS ONE 3:e2391. 2008
    ..7 ng/ml) (58.7% and 19.2%, respectively; P<0.0001). Serum AFP should be added to the list of factors predictive of treatment response in chronic hepatitis C...
  92. doi request reprint Why actively promote vaccination in patients with cirrhosis?
    Pierre Loulergue
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Clin Virol 46:206-9. 2009
    ..Few data regarding vaccination coverage are available, but studies suggest that immunization rates are too low in this population...
  93. ncbi request reprint [Hepatitis B virus genotypes: clinical, epidemiological and therapeutic implications]
    Philippe Halfon
    Departement de Virologie, Laboratoire Alphabio, Marseille
    Gastroenterol Clin Biol 26:1005-12. 2002
  94. ncbi request reprint [New recommendations for diagnosis and virological monitoring of viral hepatitis]
    Stanislas Pol
    Gastroenterol Clin Biol 27:89. 2003
  95. ncbi request reprint Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)
    Eric Rosenthal
    Service d Hematologie Clinique, Hopital Archet, Nice, France
    AIDS 17:1803-9. 2003
    ....
  96. ncbi request reprint Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis
    Armand Abergel
    Services d Hépato gastroentérologie, Hotel Dieu, Clermont Ferrand, France
    Eur J Gastroenterol Hepatol 16:1219-27. 2004
    ..Studies of viral hepatitis C have suggested that fibrosis can regress, at least in patients with sustained virological response. A recent study suggested that cirrhosis was reversible in sustained and non-virological responders...
  97. ncbi request reprint The core-specific precursor T cell response is directed to the N-terminal and central parts of the protein and positively correlates to the viral load in chronically HCV-infected patients
    Geneviève Janvier
    Unite Postulante d Immunopathologie Virale, URA CNRS 1930, Institut Pasteur, Bat Lwoff, Paris
    Virology 340:318-25. 2005
    ....
  98. ncbi request reprint [The irreversibility of cirrhosis: "the jostle dogma"]
    Laetitia Fartoux
    Unité d Hépatologie, hôital Necker, 75743 Paris
    Rev Prat 55:1549-51. 2005
  99. ncbi request reprint Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study
    Jean Francois Cadranel
    Centre Hospitalier Laennec, Service d Hépato Gastroentérologie et de Diabétologie, boulevard Laennec, BP 72, 60109 Creil
    Gastroenterol Clin Biol 31:180-4. 2007
    ..This observational study aimed at evaluating the satisfaction of patients with chronic hepatitis C using the peginterferon (peg-IFN) alfa-2b pen device...
  100. pmc Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients
    Christopher Payan
    Départment de Microbiologie EA3882, CHU Hôpital Morvan, Brest, France
    Gut 56:1111-6. 2007
    ....
  101. ncbi request reprint Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
    Firouzé Bani-Sadr
    J Acquir Immune Defic Syndr 45:123-5. 2007